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Mie University School of Medicine, Tsu, Mie, JapanObjective. The aim of this study was to evaluate the efficacy, safety, and feasibility of pulse-spray pharmacomechanical
thrombolysis to treat proximal deep vein thrombosis (DVT) in conjunction with the placement of a non-permanent IVC
filter.
Methods. We studied 31 consecutive patients with acute proximal DVT defined as the inferior vena cava (IVC), iliac vein
and/or femoral vein, who were diagnosed using duplex ultrasonography and/or contrast venography. All were treated with
pulse-spray urokinase. Early success was assessed by comparing the pre- and post-treatment venographic severity score.
Non-permanent IVC filters were used to reduce the risk of pulmonary thromboembolism.
Results. The average total urokinase dose was 1.71 million IU (range: 0.72–3.6 million IU) and the average duration of
therapy was 2.4 days. The average percentage of thrombus lysed was 85% (range: 22–100%). A large thrombus trapped by
the filter was detected using cavography before extraction of the filter in one patient. There was no major treatment-related
adverse event.
Conclusion. The combination of pulse-spray pharmacomechanical thrombolysis and the prophylactic use of a non-
permanent IVC filter was a safe and effective approach for treating acute proximal DVT.Keywords: Deep vein thrombosis; Clinical trials; Fibrinolytic therapy; Intravascular devices; Pulmonary embolism.Introduction
Deep vein thrombosis (DVT) can cause both pulmon-
ary thromboembolism (PTE) and post-thrombotic
syndrome. DVT treatment aims to relieve the acute
symptoms of limb swelling and pain, reduce the risk of
PTE, and prevent long-term disability from chronic
venous insufficiency including persistent limb pain
and swelling, hyperpigmentation, venous claudica-
tion, and skin ulceration. Early thrombolysis seems to
be important to preserve valvular function.1,2 How-
ever, conventional treatment strategies, including
anticoagulation and systemic thrombolytic therapy,
do not lead to rapid resolution of proximal DVT. It has
been reported that only 6% of patients treated with
standard heparin anticoagulation alone for DVT of a
lower extremity achieve clot lysis within 10 days of
treatment,3 and thrombus propagation is seen in up to
40% despite adequate anticoagulation.4 Systemicing author. Norikazu Yamada, MD, First Department of
dicine, Mie University, 2-174 Edobashi, Tsu, Mie
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but seems less effective than catheter-directed throm-
bolysis probably because of poor penetration of
thrombi by the drugs which have been used.6 A recent
report found that venous valvular function was better
preserved in patients with iliofemoral DVT treated
with catheter-directed thrombolysis than systemic
thrombolysis.7 Although catheter-directed thromboly-
sis can be effective,8–21 the high daily dose of
thrombolytic drug increases the risk of haemorrhage
and can cause serious bleeding complications.22
Pulse-spray pharmacomechanical thrombolysis in
which a highly concentrated fibrinolytic agent is
injected directly into the thrombus as a brief high-
pressure spray via multiple side hole ports in the
catheter, has been used primarily to treat peripheral
arterial occlusions. Pulse-spray pharmacomechanical
thrombolysis for DVT appears superior to convention-
al catheter infusion thrombolysis in fragmenting and
lysing the clot,23–25 but only a few case reports have
been published.26–28 The routine use of an inferior
vena cava (IVC) filter was not recommended for
conventional catheter infusion thrombolysis forEur J Vasc Endovasc Surg 31, 204–211 (2006)
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Pharmacomechanical Thrombolysis for DVT 205proximal DVT except for patients with poor cardio-
vascular reserve or patients with large, free-floating
thrombi in the IVC.16 However, a non-permanent IVC
filter was used before pulse-spray pharmacomechani-
cal thrombolysis in this study because of the potential
risk of pulmonary thromboembolism due to fragmen-
tation of thrombi.
The combination of pulse-spray pharmacomecha-
nical thrombolysis and non-permanent IVC filter
placement should theoretically maximize the
likelihood of successful thrombolysis while minimiz-
ing the risk of PTE and bleeding complications. The
purpose of this study was to evaluate the efficacy,
safety and feasibility of pulse-spray pharmacomecha-
nical thrombolysis in conjunction with the placement
of a non-permanent IVC filter for treating proximal
DVT.Patients and Methods
Between June 2002 and June 2004, patients were
enrolled when they fulfilled the following three
inclusion criteria: (1) DVT confirmed using duplex
ultrasonography and/or contrast venography, (2)
thrombus observed in proximal veins, including IVC,
iliac vein, and femoral vein, (3) clinical symptoms
(duration of %30 days) such as swelling and pain.
Exclusion criteria were: (1) Limb ischemia, (2)
previous DVT of the ipsilateral limb, (3) contra-
indications to contrast media, anticoagulation, or
thrombolytic agents, and (4) refusal of the treatment
by the patient. After duplex ultrasonography,
enhanced computed tomography and/or contrast
ascending venography were performed to evaluate
the extent of the thrombus. Lung scan, multidetector
computed tomography and/or pulmonary angiogra-
phy was performed to establish the presence or
absence of pulmonary embolism before the procedure.
Non-permanent IVC filters (Neuhaus Protect filter
(Neuhaus Laboratories Inc., Miami, FL, USA), Antheor
filter (Boston Scientific Corp., Natick, MA, USA) and
Gu¨nther tulip filter (William Cook Europe, Bjaevers-
kov, Denmark)) were used. In cases of DVT involving
the femoral vein, the catheter was always inserted
through a popliteal vein in the supine position with
the knee slightly flexed, and the leg rotated. In cases of
DVT limited to the IVC and iliac vein, the catheter was
inserted through the ipsilateral femoral vein.
Pharmacomechanical thrombolysis was performed
using a Fountain infusion catheter (Merit Medical
Systems Inc., South Jordan, UT, USA) with 80–320 side
holes at 1.25 mm intervals in a spiral pattern.
A penetrating spray was emitted from the side holesby manual injection. The catheter was positioned with
the aid of a guidewire so that the side holes contacted
most of the thrombus; the most proximal side hole was
placed at the proximal edge of the thrombus. The
guidewire was exchanged for a tip-occluding wire,
which was inserted to close the end hole of the
catheter, and the catheter was connected with a
Y-shaped adaptor to facilitate drug injections around
the wire.
The urokinase dose was 720,000 IU/day. The
thrombolytic solution was prepared by dissolving
240,000 IU of urokinase in 50 ml of saline, and 240,
000 IU per injection was administered three times a
day. To maximize penetration into the thrombus,
approximately 50 forceful and rapid manual pulse
injections of 0.5- to 1.0-ml with the Squirt fluid
dispensing system (Merit Medical Systems Inc.,
South Jordan, UT, USA) were administered manually
about every 10 s. Progress was assessed at 1 or 2 day
intervals by venography through the catheter (Fig. 1).
Thrombolytic therapy was terminated when recanali-
sation and brisk venous flow was obtained or no
progress was observed.
All patients received concomitant continuously
infused heparin during the procedure through the
catheter or the side port of the introducer sheath. The
heparin dose was adjusted to control the activated
partial thromboplastin time twice the control value.
After the procedure, heparin was continued until
therapeutic anticoagulation with warfarin was
achieved.
The extent of clot lysis was assessed using a scoring
system based on pre- and post-treatment venography.
All venographic images were read and the score was
calculated independently by two trained observers
blinded to the clinical data. As we considered that
venous recanalisation is effective for early symptom
relief such as limb pain and swelling, an original
scoring system was adopted in this study to discrimi-
nate occluded segments from non-occluded segments
post-treatment. The score was calculated for nine
venous segments of the upper, middle and lower IVC;
the common iliac vein; the external iliac vein; the
common femoral vein; the proximal and distal
portions of the femoral vein, and the popliteal vein.
The score was classified into seven categories accord-
ing to the extent and form of thrombus; 0: No
thrombus, 1: Thrombus extended over 1/3 of the
length of the venous segment without occlusion, 2:
Thrombus extended over 2/3 of the length of the
venous segment without occlusion, 3: Thrombus
extending along the entire length of the venous
segment without occlusion, 4: Thrombus extending
over 1/3 of the length of the venous segment withEur J Vasc Endovasc Surg Vol 31, 2 2006
Fig. 1. Pre-treatment venogram showing abrupt and complete occlusion of the left iliac and femoral veins with poor collateral
flow (A). Venogram 2 days after pulse-spray pharmacomechanical thrombolysis showed recanalisation of these veins (B).
N. Yamada et al.206occlusion, 5: Thrombus extending over 2/3 of the
length of the venous segment with occlusion, 6:
Thrombus extending the entire length of the venous
segment with occlusion. The total scores before and
after treatment were then calculated by adding the
scores of the nine venous segments. The difference
between the pre- and post-treatment scores divided by
the pre-treatment score and multiplied by 100 was
classified as the percentage of thrombolysis achieved.
After thrombolysis, further intervention consisting of
balloon angioplasty or stent implantation was per-
formed if there was an underlying significant venous
stenosis. The post-treatment venographic severity
score was calculated before additional adjunctive
intervention. After the cavogram was obtained, the
filter was extracted unless a definitive trapped clot
was detected. If a trapped clot was demonstrated, the
filter was extracted after the clot was dissolved by
systemic thrombolysis.Eur J Vasc Endovasc Surg Vol 31, 2 2006The Ethics Committee of Mie University Hospital
approved the study, and written informed consent was
obtained from each enrolled patient.Results
We recruited 31 patients (15 men and 16 women, mean
age, 56 years, range: 19–81 years). Eleven patients were
excluded from this study because of prior DVT of the
ipsilateral limb in six patients and contraindication of
thrombolytic therapy in five patients. The location of
the thrombus and the treatment details are summar-
ized in Tables 1 and 2. The median duration from onset
to treatment was 9 days (range: 2–29 days). Left limbs
were more frequently involved than right limbs
(24 vs. 7). All patients had proximal DVT including
thrombosis in the IVC, iliac and/or femoral vein.
Before treatment, 18 patients had PTE detected
Table 1. Patient characteristics
No.
Male gender 15 (48)
Duration from onset to therapy
7 days 18 (58)
8–14 days 9 (29)
15–30 days 4 (13)
Location of thrombus
Left 24 (77)
Right 7 (23)
Iliofemoral 23 (74)
With extension to the IVC 6 (19)
Without extension to the IVC 17 (55)
Iliac 2 (6)
With extension to the IVC 2 (6)
Without extension to the IVC 0 (0)
Femoral 6 (19)
PTE before therapy* 18 (58)
Numbers in parentheses are percentages.
* The diagnosis of PTE was confirmed by objective tests
(pulmonary angiography, multidetector computed tomography,
lung scan).
Fig. 2. Venographic severity score before and after pulse-
spray pharmacomechanical thrombolysis (error bars: Mean
and standard deviation. *p!0.0001 (paired t-test)).
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ography and/or pulmonary angiography. The most
favoured access site for the catheter was the ipsilateral
popliteal vein. Successful placement of the thrombo-
lysis catheter across the occluded vein was obtained in
all cases. All patients received urokinase as the
thrombolytic agent. The average total urokinase dose
was 1.71 million IU (range; 0.72–3.60 million IU) and
the average duration of therapy was 2.4 days (range:
1–5 days). The maximum length of the side hole
portion of the catheter used in this study was 40 cm. If
the length of the side hole portion was shorter than
that of the occluded venous thrombus to be treated,
the catheter was withdrawn to treat the remaining
occluded region after initial treatment. An increased
treatment duration of more than 3 days was necessary
for patients with a long venous occluded lesion.Table 2. Treatment regimen
No.
Catheter entry site
Popliteal vein 30 (97)
Femoral vein 1 (3)
Non-permanent IVC filter
Antheor 2 (6)
Neuhaus 2 (6)
Gu¨nther 27 (87)
Total dose of UK (million IU)
1.0 6 (19)
1.0–2.0 13 (42)
2.0–3.0 11 (36)
3.0–4.0 1 (3)
Additional intervention
Balloon angioplasty 3 (10)
StentCballoon angioplasty 5 (16)
Numbers in parentheses are percentages.The average lytic rate, the percentage of thrombus
in which thrombolysis was achieved, was 85% (range:
22–100%) (Fig. 2). A suboptimal lysis rate of less than
50% was recognized in one patient (3.2%) with
residual organized thrombus secondary to iliac
compression syndrome. Acute venous reocclusion
occurred in a patient with advanced lung cancer at 2
weeks after treatment. No filter migration was
observed during implantation period. In one patient,
a large thrombus trapped by the filter was detected
through cavography before extraction of the filter
(Fig. 3). This patient was treated with the systemic
administration of additional urokinase of 480,000 IU/
day for 4 days. The non-permanent IVC filter was
extracted after recognition of clot lysis through follow-
up cavography. Moreover, although cavography could
not definitely detect any trapped thrombus on the
filter, a small thrombus was attached to the filter in 18
patients. No patients experienced symptomatic or fatal
PTE. There were no major treatment-related adverse
events, but one minor event: One patient experienced
a small hematoma at the puncture site of catheter
insertion. After pulse-spray thrombolysis, additional
interventions were performed successfully for eight
patients with residual venous stenoses resistant to
thrombolysis; balloon angioplasty in eight patients
and self-expandable metallic stent (Wallstent; Schnei-
der, Minneapolis, USA) implantation for the common
iliac vein in five patients (Fig. 4).Eur J Vasc Endovasc Surg Vol 31, 2 2006
Fig. 3. Cavogram 2 days after pulse-spray pharmacomechanical thrombolysis showed thrombus trapped by the filter (left:
Frontal image, right: Lateral image).
Fig. 4. Pre-treatment venogram showing abrupt and complete occlusion of left common femoral and iliac veins with poor
collateral flow (A). Contrast media injected through the pulse-spray catheter penetrated the obstructing thrombus (B). Brisk
flow was restored in the common femoral and iliac veins after pulse-spray pharmacomechanical thrombolysis, but significant
residual stenosis of the left common iliac vein was demonstrated (C). After percutaneous balloon venoplasty (D), a wall stent
was inserted in the left common iliac vein (E).
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graphy (nZ21) or enhanced multidetector computed
tomography (nZ3) was performed in 24 of 31 limbs at
a mean post-treatment period of 11.1 months (range:
3–24 months), showing continued patency of the
treated veins in 22 of 24 (91.7%). Objective clinical
signs of post-thrombotic syndrome such as limb
swelling, hyperpigmentation, chronic eczema and
skin ulceration were evaluated in 30 of 31 limbs at a
mean post-treatment period of 23.1 months (range:
13–37 months). Only one patient showed affected limb
swelling as post-thrombotic syndrome 24 months after
the procedure. Duplex ultrasound scanning with
6 MHz linear array transducer was performed to
assess the venous reflux in 24 of 31 limbs at a mean
post-treatment period of 25.1 months (range: 13–37
months). The patients were studied in the standing
position. An automatic cuff inflator was used to induce
the venous reflux with a maximum pressure of
80 mmHg for rapid inflation and deflation cuffs placed
on the calf. Venous segments including the common
femoral vein, femoral vein below the confluence with
the profunda vein, popliteal vein and proximal great
saphenous vein were evaluated. Cut-off values for the
duration of reflux were defined as more than 1000 ms
for common femoral vein, femoral vein and popliteal
vein and more than 500 ms for great saphenous vein.29
Significant reflux was observed in three patients; the
durations of reflux were 1280 ms at common femoral
vein and 1260 ms at popliteal vein in one patient with
affected limb swelling, 3700 ms at popliteal vein and
3570 ms at common femoral vein, respectively, in two
patients without leg symptoms.Discussion
Pulse-spray pharmacomechanical thrombolysis con-
sists of brief high-pressure pulsed injections of a
concentrated fibrinolytic agent throughout the clot via
a multi-side-hole catheter. This method is expected to
have the following advantages:24,25 (1) Macerating the
clot and increasing the contact area of the thrombus
with the thrombolytic agent by penetrating intra-
thrombic injections, (2) increasing the rate of lysis by
applying the concentrated agent, (3) minimizing the
dilution of the thrombolytic agent, systemic effects and
effect of plasmin inhibitors in plasma owing to
retention of the thrombolytic agent in the thrombus,
(4) increasing the rate of lysis by simultaneous
treatment of the entire thrombus, and (5) reduction
of the cost and potential bleeding problems associated
with the use of thrombolytic agents. Bookstein et al.
describe the original technique of pulse-spraypharmacomechanical thrombolysis for the treatment
of dialysis graft and arterial bypass graft occlusion.25
For graft occlusion, it has been reported that the pulse-
spray method appears more effective than the
conventional selective infusion method of catheter-
directed thrombolysis.24,30–32 In an experimental study
with animal models, the pulse-spray method was
shown to be more effective than the conventional
infusion method.23 It appears that the increased clot
surface caused by maceration using the pulse-spray
method is the main contributor to improvement of the
rate of thrombolysis in patients with occluded grafts.
For patients with proximal DVT, this pulse-spray
method is also expected to be more effective than
catheter-directed infusion thrombolysis because of the
macerating effect by emitting fluids. To our knowl-
edge, only a few case reports on pulse-spray
pharmacomechanical thrombolysis for DVT have
been published,26–28 although more than 10 reports
of catheter-directed infusion thrombolysis for DVT
have recently been published.8–21
Pulse-spray pharmacomechanical thrombolysis is
especially advantageous in patients with completely
occluded venous thrombosis. Thery et al., in a
prospective study of 174 patients with proximal
extensive DVT, reported that the thrombus is com-
pletely lysed with systemic infusion therapy of
streptokinase in 60% of patients with non-occlusive
clots compared with 14% among those with complete
occlusion.33 Systemic thrombolysis might be less
effective for occlusive clots than catheter-directed
thrombolysis because of the difficulty in the drug
penetrating thrombi.
The average total urokinase dose in one previous
report of catheter-directed infusion thrombolysis of a
multicentre registry was 7.8 million IU,21 and major
bleeding complications were reported in 11% of
patients in this study.21 More than 2000–2500 IU/kg/
h (2.88–3.6 million IU/day for patients weighing
60 kg) was used in another previous report of
catheter-directed infusion thrombolysis.16 The results
of this study indicated that a much lower daily
urokinase dose (0.72 million IU/day, average total:
1.71 million IU) was sufficient to lyse the thrombus
and recanalise the occluded vein when using pulse-
spray pharmacomechanical thrombolysis. This low
daily dosage of urokinase might also reduce the
incidence of bleeding complications.
The necessity of filter placement has been a very
controversial topic in catheter-directed thrombolysis.16
Ultra-high-dose thrombolytic therapy is known to
have an approximately 6% risk of fatal PTE if iliac or
iliocaval thrombosis is present without an IVC filter.34
Mewissen et al. reported that the true prevalence ofEur J Vasc Endovasc Surg Vol 31, 2 2006
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in six of 287 patients and one was fatal during catheter-
directed thrombolysis.21 One study demonstrated PTE
in 59% of patients undergoing haemodialysis graft
thrombolysis using a modified pulse-spray technique
with a large pulse volume (3–5 ml).35 Kinney et al.
reported that 54.5 and 71.4% of patients experienced
new perfusion defects after pulse-spray pharmaco-
mechanical thrombolysis with urokinase and hepar-
inised saline, respectively, among patients with clotted
haemodialysis grafts.36 Concerns have been raised
about the risk and significance of PTE produced by
this method. The prophylactic use of a non-permanent
IVC filter may be appropriate to prevent clinically
significant PTE during pulse-spray pharmacomecha-
nical thrombolysis in patients with acute proximal
DVT.
This study had some limitations: First, the post-
treatment objective test for PTE associated with this
therapy was not performed. Although symptomatic or
fatal PTE did not occur in this study, the rate of
asymptomatic PTE was not clarified. The safety of this
method for patients with severely compromised
cardiopulmonary reserve was unclear; second, further
study is needed to determine the optimal dosing
regimens and frequency of administration for this
method; third, although clinical trials demonstrating
that rapid lysis of DVT improves the long-term clinical
outcome are few and limited,37,38 early thrombolysis
appeared beneficial to prevent chronic venous insuffi-
ciency.7 Further study is necessary to evaluate the role
of restoring the early patency of treated veins in the
prevention of late or chronic sequelae of DVT.Conclusions
The combination of pulse-spray pharmacomechanical
thrombolysis and the prophylactic use of a non-
permanent IVC filter was a safe and effective approach
for treating acute proximal DVT. Future large pro-
spective studies will be necessary to confirm the
superiority of this approach in terms of early lytic
rate, safety and long-term sequelae.Acknowledgements
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